Sareum Holdings plc (LSE:SAR) is a small-cap drug developer whose news flow this year has been almost entirely about one molecule: SDC-1801, an oral TYK2/JAK1 inhibitor aimed at psoriasis and other autoimmune diseases. On 20 July 2026 the company said dosing in its Phase 2-enabling toxicology programme had finished on schedule and within existing cash, putting a complete regulatory package within reach by the fourth quarter of 2026. That package is the gate to Phase 2 trials and to the partnering talks Sareum is pursuing.
The question for 2026 is whether a Business with no revenue, £2.5m of cash at its last balance-sheet date and a Market Value of around £31m can convert a clean Phase 1 dataset into a licensing deal before its cash runs short. That tension is what makes SAR worth watching, and what makes it risky.
Toxicology dosing complete, Phase 2 package targeted for Q4 2026
The 20 July 2026 announcement closed a difficult chapter. Sareum began longer-term toxicology studies for SDC-1801 in May 2025, but on 10 October 2025 disclosed that a 16-week GLP study had been discontinued because of control-group findings it said were unrelated to the compound. A new contract research organisation was appointed and the programme restarted on 17 February 2026.
Dr Stephen Parker, Executive Chairman, said he was "pleased to see the Phase 2-enabling toxicology programme completed on schedule, using existing cash resources." Chief Scientific Officer Dr John Reader said the milestone built on "the encouraging Phase 1 results, which showed a pharmacokinetic profile consistent with once-daily dosing and no safety concerns." Data analysis, Manufacturing and formulation work continue, with the full regulatory package targeted for Q4 2026.
Supporting evidence arrived on 22 June 2026, when Phase 1 data were published in the British Journal of Clinical Pharmacology. The placebo-controlled study in 95 healthy adults reported no treatment-related serious adverse events and a half-life of 15 to 27 hours, with dose-dependent reductions in inflammatory biomarkers.
What Sareum does
Sareum is a clinical-stage drug discovery and development company quoted on AIM since 2004. It sells no products; its model is to advance small-molecule candidates through early development and license them to larger pharmaceutical partners for upfront payments, milestones and royalties.
The lead asset, SDC-1801, targets the TYK2 and JAK1 kinases, a pathway validated by approved psoriasis medicines. A sister compound, SDC-1802, is positioned as a cancer immunotherapy for haematological cancers, and the board has concluded it "will be best progressed by a partner."
The third asset is SRA737, a Chk1 inhibitor. In March 2025 Sareum acquired a licence to the compound at no cost, lifting its share of future revenues to 63.5% from 27.5%. SRA737 has Phase 1/2 data in anogenital cancers and an active FDA IND for a leukaemia trial. A collaboration with Receptor.AI, announced in August 2025, is seeking brain-penetrant TYK2 inhibitors for neurological disease.
Latest financials: half-year loss widens, cash £2.5m
Sareum's half-year report for the six months to 31 December 2025, published on 12 March 2026, showed no revenue, a loss before tax of £1.9m (H1 FY25: £1.3m) and a loss after tax of £1.7m. Administrative expenses, including R&D, were £1.8m, of which R&D was £1.4m. Loss per share was 1.2p.
Cash stood at £2.5m at 31 December 2025, down from £3.5m at 30 June 2025 and £4.1m at 31 December 2024. Inflows were modest: £0.5m from Warrant exercises and £0.1m of R&D tax credits, against £1.2m of credits a year earlier. The directors nonetheless stated that cash, together with amounts projected to be received, would cover at least one year from approval of the interim accounts.
For the year to 30 June 2025, preliminary results on 23 October 2025 showed a loss before tax of £3.06m (FY24: £4.60m), R&D spend of £2.07m and a loss per share of 2.4p (FY24: 4.2p). The company raised £4.5m that year, including a £1.07m placing at 12.5p in March 2025.
Since then the Balance Sheet has been topped up in small increments. Warrants from an October 2024 subscription, originally exercisable at 20p, were rebased to 12.5p after the March 2025 placing, and four exercises were announced between 1 May and 2 September 2026, the latest raising £39,189 and lifting the share count to 139.7m. At around 22.5p, the price quoted on LSE.co.uk on 2 September 2026, that implies a market value of roughly £31m.
What could move the shares next
The central catalyst is delivery of the complete Phase 2-enabling package for SDC-1801 in Q4 2026. Clean toxicology data would remove the overhang left by the 2025 discontinuation and allow a Phase 2 psoriasis trial to be designed.
A licensing agreement is the outcome management is working towards. Sareum has engaged a US business development consultancy to run discussions on SDC-1801 and SRA737, and a partner for SDC-1802 is a further possibility the board has flagged.
Full-year results for the year to 30 June 2026, likely in October if last year's timetable repeats, will update cash and the going-concern position.
Risks investors should watch
Funding is the dominant risk. With £2.5m of cash at 31 December 2025, half-year cash burn of roughly £1m and no revenue, Sareum will almost certainly need a licensing deal or a further Equity raise to fund a Phase 2 trial. Previous raises were priced at discounts; the March 2025 placing at 12.5p and the subsequent warrant rebasing show how terms can be reset lower.
Development risk is real. The original toxicology study was abandoned in 2025 and the full analysis of the restarted programme is not yet public; any adverse signal would undermine the partnering case. The TYK2/JAK1 field is also crowded with rivals from far better-resourced companies, and partners may Demand Phase 2 proof-of-concept before committing.
SRA737's enlarged Revenue share is only worth something if a partner funds trials Sareum cannot afford alone. The shares are illiquid, so news can produce sharp moves either way, and falling R&D tax Credit receipts shrink a source of non-dilutive cash.
Outlook
Sareum enters the final months of 2026 with a clear near-term deliverable and a narrow financial margin. If the Q4 2026 regulatory package confirms the safety picture from Phase 1, the company will have a Phase 2-ready oral TYK2/JAK1 candidate in a class that remains of interest to larger players. Whether that translates into a licensing deal, and on what terms, will determine the Investment case.
The metrics to monitor are the toxicology data, cash at 30 June 2026, the pace of warrant exercises and any word from the partnering process. The "sleeper" label fits a stock that has been quiet corporately while making steady scientific progress; the next two quarters should reveal whether that progress has commercial value.



_11_18_2026_14_37_47_487896.jpg)


Please wait processing your request...